Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
PaperCitations, authors & open-access status
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,018 citations, 2016 year and green oa status.
1,018
Citations
2016
Year
green
OA Status